Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OPRX
BUYFLAGOptimizeRx Corporation · Healthcare · United States · $117M · Avg Vol: $3M/d
OptimizeRx has quality Q68 and value V75, but momentum at M32 is well below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
OptimizeRx Corporation is a digital health technology company that connects pharmaceutical manufacturers with healthcare providers and patients at the point of care. The company's platform integrates directly into electronic health record (EHR) and e-prescribing workflows, creating a high-barrier-to-entry distribution network. Its competitive moat lies in its ability to deliver targeted clinical and financial information to physicians in real time.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.5M | 71.5M | 92.1M | 109.4M | 20.6% | 107.3M | 97.4M | 108.9M | -0.2% |
| EPS | -0.64 | -1.03 | -1.10 | 0.28 | — | 0.35 | 0.25 | 0.29 | 1.8% |
| Shares | 17.1M | 18.2M | 18.5M | 18.8M | +9.9% | 18.8M | — | — | — |
| Debt | 0.2M | 36.8M | 33.2M | 26.1M | 381.1% | 23.7M | — | — | — |
| Equity | 126.1M | 126.6M | 117.0M | 128.3M | 0.6% | — | — | — | — |
| Op CF | 10.7M | -7.2M | 4.9M | 18.7M | 20.7% | 14.4M | — | — | — |
| Inv CF | -58.2M | -25.3M | -0.5M | 68.0K | — | — | — | — | — |
| Fin CF | -19.0M | 28.2M | -4.9M | -8.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OPRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OPRX | OptimizeRx Corporation(you) | $117M | 77 | BUY |
| AMWL | American Well Corporation | $181M | 68 | BUY |
| CCLD | CareCloud, Inc. | $94M | 93 | STRONG BUY |
| SLP | Simulations Plus, Inc. | $371M | 77 | BUY |
| SPOK | Spok Holdings, Inc. | $221M | 90 | STRONG BUY |
| NURS.V | Hydreight Technologies Inc. | $167M | 55 | HOLD |
| NRC | NRC Health | $474M | 73 | BUY |
| MDRX | Veradigm Inc. | $517M | 65 | HOLD |
| HCAT | Health Catalyst, Inc. | $154M | 40 | HOLD |
| GDRX | GoodRx Holdings, Inc. | $1.0B | 77 | BUY |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%